Detail akcie Provexis online

Business Summary: Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
Financial Summary: BRIEF: For the fiscal year ended 31 March 2024, Provexis plc revenues increased from L390K to L802K. Net loss increased 52% to L586K. Revenues reflect Fruitflow +nitrates development product segment increase from L74K to L652K, Fruitflow+omega 3 segment increase of 3% to L150K. Higher net loss reflects Administrative costs - share-based payme increase from L41K to L121K (expense), Research and development costs increase of 27% to L302K (expense).